XML 36 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900
Equity Instruments (Tables)
6 Months Ended
Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
time of the grant for treasury securities of similar maturity. Aytu has computed the fair value of all options granted during the six months ended December 31, 2015 using the following assumptions:
 
Expected volatility
 
75.00
%
Risk free interest rate
 
1.08% - 2.08
%
Expected term (years)
 
3.0 - 7.0
 
Dividend yield
 
0
%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Stock option activity is as follows:
 
 
 
Number of 
Options
 
Weighted
Average 
Exercise Price
 
Weighted Average 
Remaining Contractual
Life in Years
 
Outstanding June 30, 2015
 
-
 
$
-
 
 
 
Granted
 
3,695,000
 
$
1.55
 
 
 
Exercised
 
-
 
$
-
 
 
 
Forfeited/Cancelled
 
-
 
$
-
 
 
 
Outstanding December 31, 2015
 
3,695,000
 
$
1.55
 
9.80
 
Exercisable at December 31, 2015
 
1,120,000
 
$
1.51
 
9.87
 
Available for grant at December 31, 2015
 
6,305,000
 
 
 
 
 
 
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
The following table summarizes stock-based compensation expense for the three and six months ended December 31, 2015 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three and six months ended December 31, 2014:
 
 
 
Three Months Ended December 31,
 
Six Months Ended December 31,
 
 
 
2015
 
2014
 
2015
 
2014
 
Research and development expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock options
 
$
20,000
 
$
117,000
 
$
25,000
 
$
207,000
 
Selling, general and administrative expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock options
 
$
163,000
 
$
159,000
 
 
226,000
 
 
271,000
 
 
 
$
183,000
 
$
276,000
 
$
251,000
 
$
478,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unrecognized expense at December 31, 2015
 
$
1,890,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted average remaining years to vest
 
 
3.16
 
 
 
 
 
 
 
 
 
 
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
A summary of these warrants is as follows:
 
 
 
Number of 
Warrants
 
Weighted 
Average 
Exercise Price
 
Weighted Average 
Remaining Contractual
Life in Years
 
 
 
 
 
 
 
 
 
 
Outstanding June 30, 2015
 
102,613
 
$
4.53
 
2.92
 
Outstanding December 31, 2015 (unaudited)
 
102,613
 
$
4.53
 
2.41